NAD+ Boosting and SIRT1 Activation to Reverse Cellular Senescence in Neurons

In-Vitro Score: 0.850 Price: $0.50 Alzheimer disease Primary cortical neurons from aged (18-month) mice or SAMP8 Status: proposed

What This Experiment Tests

In-Vitro experiment designed to assess clinical efficacy targeting N/A in Primary cortical neurons from aged (18-month) mice or SAMP8. Primary outcome: NAD+/NADH ratio, SA-β-gal positivity, mitochondrial OCR

Description

Evaluate whether NAD+ precursor supplementation (NMN) activates SIRT1/PGC1α signaling, restores mitochondrial function, and reduces senescence markers in aged neurons and senescence-accelerated mouse model (SAMP8).

TARGET GENE

N/A

MODEL SYSTEM

Primary cortical neurons from aged (18-month) mice or SAMP8

ESTIMATED COST

$35,000

TIMELINE

8 months

PATHWAY

N/A

SOURCE

auto-generated

PRIMARY OUTCOME

NAD+/NADH ratio, SA-β-gal positivity, mitochondrial OCR

Scoring Dimensions

Protocol

in-vitro

Expected Outcomes

NMN treatment increases NAD+/NADH ratio >2-fold, elevates SIRT1 activity, reduces SA-β-gal positivity by >40%, and restores mitochondrial oxygen consumption rate (OCR).

Success Criteria

NAD+/NADH ratio (colorimetric assay), SA-β-gal assay, mitochondrial OCR (Seahawk); threshold: p < 0.05 vs. aged vehicle control.

Related Hypotheses (0)

No related hypotheses

Debate History (0)

No debates yet

Experiment Results (0)

No results recorded yet. Use POST /api/experiments/{id}/results to record a result.